Dark Streaming/Mobile Old Site Home Products Help Contact Us Your Account System Status
Sign-up for a FREE 30-day Stockwatch subscription and SEE NO ADS
00:39:45 EDT Mon 29 Apr 2024
Enter Symbol
or Name
USA
CA



News for U:IPHA from 2023-04-30 to 2024-04-29 - 46 items News ReleasesIn The NewsOther CAUS
DateSymPriceTypeHeadline
2024-04-15 01:00U:IPHANews ReleaseInnate Pharma to Hold Its Annual General Meeting of Shareholders on May 23, 2024
2024-04-15 01:00U:IPHANews ReleaseInnate Pharma Announces Advancement of Sanofi-developed NK Cell Engager SAR443579 / IPH6101 Progressing to Phase 2 for Blood Cancer Patients
2024-04-10 01:00U:IPHANews ReleaseInnate Pharma Presents at AACR 2024 Preclinical Efficacy of Its Pre-IND Drug Candidate IPH45, a Novel Nectin-4 Antibody Drug Conjugate
2024-04-09 01:00U:IPHANews ReleaseInnate Pharma Announces Its Participation in Upcoming Investor Conference
2024-04-05 03:34U:IPHANews ReleaseInnate Pharma Files Its 2023 Universal Registration Document (Document d'enregistrement Universel) and 2023 Annual Report on Form 20-F
2024-03-21 02:00U:IPHANews ReleaseInnate Pharma Reports Full Year 2023 Financial Results and Business Update
2024-03-19 02:00U:IPHANews ReleaseInnate Pharma Announces Its Participation to Upcoming Investor Conference
2024-03-14 02:00U:IPHANews ReleaseInnate Pharma Announces Conference Call and Webcast for Full Year 2023 Financial Results
2024-03-06 01:00U:IPHANews ReleaseInnate Pharma to Present Nectin-4 Antibody Drug Conjugate IPH45 Preclinical Data at AACR 2024
2024-03-06 01:00U:IPHANews ReleaseInnate Pharma: First Patient dosed in Phase 1/2 study of IPH6501 in relapsed /refractory B-Cell non-Hodgkin's Lymphoma
2024-02-21 01:00U:IPHANews ReleaseInnate Pharma Announces Its Participation to Upcoming Investor Conference
2024-01-12 01:00U:IPHANews ReleaseNumber of Shares and Voting Rights of Innate Pharma as of January 1, 2024
2024-01-04 01:00U:IPHANews ReleaseInnate Pharma Announces U.S. FDA Lifts Partial Clinical Hold on Lacutamab Clinical Program
2024-01-04 00:59U:IPHANews ReleaseInnate Pharma Strengthens Leadership and Appoints Two New Members to Its Executive Board
2023-12-19 01:00U:IPHANews ReleaseInnate Pharma Announces Licensing of a Fourth Natural Killer Cell Engager in Oncology to Sanofi
2023-12-18 01:00U:IPHANews ReleaseInnate Pharma Announces Leadership Change
2023-12-11 01:00U:IPHANews ReleaseInnate Pharma Shares Efficacy and Safety Phase 1 /2 Results of NK Cell Engager SAR443579 / IPH6101 Developed by Sanofi at ASH 2023
2023-12-10 01:00U:IPHANews ReleaseInnate Pharma Presents Positive Results From TELLOMAK Phase 2 Study With Lacutamab in Patients With S ƒ ©zary Syndrome at ASH 2023
2023-11-14 01:00U:IPHANews ReleaseInnate Pharma Reports Third Quarter 2023 Financial Results and Business Update
2023-11-07 01:00U:IPHANews ReleaseInnate Pharma Announces Conference Call for Third Quarter 2023 Business Update
2023-11-03 02:00U:IPHANews ReleaseInnate Pharma Announces New Clinical Data for Lacutamab and SAR443579/IPH6101 at ASH 2023
2023-10-27 01:00U:IPHANews ReleaseInnate Pharma Announces Its Participation to Upcoming Investor Conferences
2023-10-19 01:00U:IPHANews ReleaseInnate Pharma 2024 Financial Calendar
2023-10-16 01:00U:IPHANews ReleaseInnate Pharma Announces Abstracts Selected for ESMO Congress 2023
2023-10-09 01:00U:IPHANews ReleaseNumber of Shares and Voting Rights of Innate Pharma as of October 3, 2023
2023-10-05 01:00U:IPHANews ReleaseInnate Pharma Provides Update on Lacutamab Clinical Program
2023-09-22 01:00U:IPHANews ReleaseInnate Pharma Announces Encore Presentation of Interim Results of Phase 2 TELLOMAK Study With Lacutamab With Updated Olsen 2022 Criteria at the EORTC Cutaneous Lymphoma Tumour Group Annual Meeting 2023
2023-09-14 01:00U:IPHANews ReleaseInnate Pharma Reports First Half 2023 Financial Results and Business Update
2023-08-29 01:00U:IPHANews ReleaseInnate Pharma Announces Its Participation to Upcoming Investor Conferences and Conference Call for First Half 2023 Business Update
2023-08-10 01:00U:IPHANews ReleaseInnate Pharma to Participate in Upcoming Investor Conference
2023-07-11 01:00U:IPHANews ReleaseFirst Patient Dosed in SAR ¢ € ™514 / IPH6401 Phase 1/2 Clinical Trial in Relapsed/Refractory Multiple Myeloma
2023-07-07 01:00U:IPHANews ReleaseNumber of Shares and Voting Rights of Innate Pharma as of July 1, 2023
2023-06-26 01:00U:IPHANews ReleaseFirst Patient Dosed in Phase 2 MATISSE Trial of IPH5201 in Early Stage Lung Cancer
2023-06-16 01:00U:IPHANews ReleaseInnate Pharma Highlights Increased Lacutamab Clinical Activity From Interim Results of Phase 2 TELLOMAK Study With Updated Olsen Criteria
2023-06-12 01:00U:IPHANews ReleaseInnate Pharma to Present Updated Interim Phase 2 Efficacy Results of Lacutamab in Mycosis Fungoides at the International Conference on Malignant Lymphoma
2023-06-10 01:00U:IPHANews ReleaseInnate Pharma Highlights Proprietary Tetra-specific ANKET ‚ ® NK Cell Engager IPH6501 at the EHA 2023 Congress
2023-06-08 01:00U:IPHANews ReleaseSAR ¢ € ™579 / IPH6101 Receives FDA Fast Track Designation in the US for the Treatment of Hematological Malignancies
2023-06-07 01:00U:IPHANews ReleaseNumber of Shares and Voting Rights of Innate Pharma as of June 1, 2023
2023-05-26 01:00U:IPHANews ReleaseInnate Pharma Highlights Phase 1/2 Dose Escalation Safety and Preliminary Efficacy of Sanofi Developed First NK Cell Engager SAR ¢ € ™579 / IPH6101 in R/R AML
2023-05-23 01:00U:IPHANews ReleaseInnate Pharma to Participate in Upcoming Investor Conferences
2023-05-15 01:00U:IPHANews ReleaseInnate Pharma to Present IPH6501 Preclinical Data at The EHA 2023 Congress
2023-05-12 16:00U:IPHANews ReleaseOutcome of Innate Pharma ¢ € ™s 2023 Annual General Meeting
2023-05-10 01:00U:IPHANews ReleaseInnate Pharma Reports First Quarter 2023 Financial Results and Business Update
2023-05-09 01:00U:IPHANews ReleaseNumber of shares and voting rights of Innate Pharma as of May 1, 2023
2023-05-03 01:00U:IPHANews ReleaseInnate Pharma Announces Conference Call and Webcast for Q1 Business Update
2023-05-03 01:00U:IPHANews ReleaseInnate Pharma Highlights Clinical Abstracts Selected for ASCO 2023 Annual Meeting